

Mrs Fuller

Scientific and Technical Information Center

SEARCH REQUEST FORM

Requester's Full Name: BEN SACKG Examiner #: 73489 Date: 11/15/05
 Art Unit: 1626 Phone Number: 2-0704 Serial Number: 10/698,451
 Location (Bldg/Room): R0N5B3 (Mailbox #): _____ Results Format Preferred (circle) PAPER DISK

To ensure an efficient and quality search, please attach a copy of the cover sheet, claims, and abstract or fill out the following:

Title of Invention: Basic salt of thiocetic acid with L-carnitine

Inventors (please provide full names): Salvi et al.


Earliest Priority Date: _____

Search Topic:

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the desired species or variations, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any term that may have a special meaning. Give examples or relevant citations, authors, etc., if known.

For Sequence Searches Only Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.

A salt of thiocetic acid with L-carnitine of formula



where X and Y are as defined

SCIENTIFIC REFERENCE BR
Sci & Tech Inf. Ctr.

NOV 16 2005

Pat. & T.M. Office

STAFF USE ONLY

Searcher: K. Fuller

Searcher Phone #: _____

Searcher Location: _____

Date Searcher Picked Up: 11/21/05

Date Complete: 40

Searcher Prep & Review Time: _____

Online Time: 25

Type of Search

____ NA Sequence (#)

____ AA Sequence (#)

1 Sequence (#)

____ Bibliographic

____ Litigation

____ Fulltext

____ Other

Vendors and cost where applicable

____ STN _____ Dialog

____ Questel/Orbit _____ Lexis/Nexis

____ Westlaw _____ WWW/Internet

____ In-house sequence systems

____ Commercial _____ Oligomer _____ Source/Length
 _____ Interference _____ SPDI _____ Encode/Transl
 _____ Other (specify) _____



STIC Search Report

EIC 1700

STIC Database Tracking Number: 171716

**TO: Ben Sackey
Location: REM 5B31
Art Unit : 1626
November 21, 2005**

**From: Kathleen Fuller
Location: EIC 1700
REMSSEN 4B28
Phone: 571/272-2505
Kathleen.Fuller@uspto.gov**

Case Serial Number: 10/698451

Search Notes

There were only 4 CA references for these compounds. CA does not seem to index them with the hydrogen missing on the carboxy group of the propanaminium.

=> FILE REG

FILE 'REGISTRY' ENTERED AT 16:50:20 ON 21 NOV 2005

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 20 NOV 2005 HIGHEST RN 868524-25-8

DICTIONARY FILE UPDATES: 20 NOV 2005 HIGHEST RN 868524-25-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*

Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=> FILE HCAPLU

FILE 'HCAPLUS' ENTERED AT 16:50:30 ON 21 NOV 2005

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 21 Nov 2005 VOL 143 ISS 22

FILE LAST UPDATED: 20 Nov 2005 (20051120/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> D QUE

L6 2 SEA FILE=REGISTRY ABB=ON (C8H13O2S2.C7H16NO3.K/MF OR C8H13O2S2.C7H16NO3.NA/MF)
L7 4 SEA FILE=REGISTRY ABB=ON C8H13O2S2.C7H16NO3/MF
L8 1 SEA FILE=HCAPLUS ABB=ON L6
L9 3 SEA FILE=HCAPLUS ABB=ON L7
L10 19 SEA FILE=REGISTRY ABB=ON THIOCTIC
L11 3 SEA FILE=REGISTRY ABB=ON L10 AND CARNITIN?
L12 2389 SEA FILE=REGISTRY ABB=ON 16.186.1/RID
L13 144 SEA FILE=REGISTRY ABB=ON L12 AND SALT
L14 30 SEA FILE=REGISTRY ABB=ON L13 AND AMINIUM
L15 10 SEA FILE=REGISTRY ABB=ON L14 AND PROPANAMINIUM
L16 2 SEA FILE=HCAPLUS ABB=ON L11
L17 3 SEA FILE=HCAPLUS ABB=ON L15
L18 4 SEA FILE=HCAPLUS ABB=ON L8 OR L9 OR L16 OR L17

=> D L18 BIB ABS IND HITSTR 1-4

L18 ANSWER 1 OF 4 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 2005:1878 HCAPLUS
DN 142:86696
TI Treatment of skin damage using acetyl carnitine and lipoic acid
IN Perricone, Nicholas V.
PA USA
SO U.S. Pat. Appl. Publ., 8 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004265345	A1	20041230	US 2003-609777	20030630
PRAI	US 2003-609777		20030630		

AB A composition containing both acetyl carnitine and lipoic acid are topically applied to treat skin damage, such as contact dermatitis, atopic dermatitis, xerosis, eczema, rosacea, seborrhea, psoriasis, thermal and radiation burns, other types of skin inflammation, and aging. Typical comps. contain from about 0.025% to about 5%, more narrowly from about 0.5% to about 2% by weight acetyl carnitine, and from about 0.1% to about %, more narrowly from about 0.25% to about 5% lipoic acid or lipoic acid derivative in a dermatol. acceptable carrier that contains phosphatidylcholine. Many embodiments also contain at least one adjunct ingredient such as tyrosine, a fatty acid ester of ascorbic acid such as ascorbyl palmitate, a α -hydroxy acid such as glycolic acid, and/or folic acid. A preferred embodiment contains acetyl carnitine, lipoic acid, and tyrosine.

IC ICM A61K031-385

ICS A61K031-205; A61K031-375; A61K031-198

INCL 424401000; 514440000; 514554000; 514474000; 514557000; 514567000

CC 1-12 (Pharmacology)

Section cross-reference(s): 63

ST skin damage treatment acetyl carnitine lipoate compn

IT Skin, disease

(aging, treatment of; treatment of skin damage using acetyl carnitine and lipoic acid)

IT Radiation

Only 4 CA references to the Compounds

(damage, burns, treatment of; treatment of skin damage using acetyl carnitine and lipoic acid)

IT Skin, disease
(damage; treatment of skin damage using acetyl carnitine and lipoic acid)

IT Skin, disease
(dry, xerosis, treatment of; treatment of skin damage using acetyl carnitine and lipoic acid)

IT Carboxylic acids, biological studies
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(hydroxy, composition further containing; treatment of skin damage using acetyl carnitine and lipoic acid)

IT Drug delivery systems
(ointments, creams; treatment of skin damage using acetyl carnitine and lipoic acid)

IT Acids, biological studies
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(oxo, composition further containing; treatment of skin damage using acetyl carnitine and lipoic acid)

IT Skin, disease
(rosacea, treatment of; treatment of skin damage using acetyl carnitine and lipoic acid)

IT Burn
(thermal and radiation, treatment of; treatment of skin damage using acetyl carnitine and lipoic acid)

IT Drug delivery systems
(treatment of skin damage using acetyl carnitine and lipoic acid)

IT Lecithins
Phosphatidylcholines, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(treatment of skin damage using acetyl carnitine and lipoic acid)

IT Dermatitis
Eczema
Psoriasis
Seborrhea
(treatment of; treatment of skin damage using acetyl carnitine and lipoic acid)

IT 50-81-7D, Ascorbic acid, fatty acid esters 59-30-3, Folic acid, biological studies 60-18-4, L-Tyrosine, biological studies 79-14-1, Glycolic acid, biological studies 137-66-6, Ascorbyl palmitate
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(composition further containing; treatment of skin damage using acetyl carnitine and lipoic acid)

IT 462-20-4, Dihydrolipoic acid 462-20-4D, Dihydrolipoic acid, esters, amides, salts 1077-28-7, dl-Lipoic acid 1077-28-7D, dl-Lipoic acid, derivs., esters, amides, salts 3040-38-8, L-Acetyl carnitine 14992-62-2, Acetyl carnitine 816416-95-2 816416-96-3 816416-97-4 816416-98-5
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(treatment of skin damage using acetyl carnitine and lipoic acid)


IT 816416-95-2 816416-96-3 816416-98-5
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(treatment of skin damage using acetyl carnitine and lipoic acid)

RN 816416-95-2 HCAPLUS


CN 1-Propanaminium, 2-(acetyloxy)-3-carboxy-N,N,N-trimethyl-, inner salt,

mixt. with 1,2-dithiolane-3-pentanoic acid (9CI) (CA INDEX NAME)

CM 1

CRN 14992-62-2
CMF C9 H17 N O4


CM 2

CRN 1077-28-7
CMF C8 H14 O2 S2RN 816416-96-3 HCAPLUS
CN 1-Propanaminium, 2-(acetyloxy)-3-carboxy-N,N,N-trimethyl-, inner salt,
(2R)-, mixt. with 1,2-dithiolane-3-pentanoic acid (9CI) (CA INDEX NAME)


CM 1

CRN 3040-38-8
CMF C9 H17 N O4


Absolute stereochemistry.




CM 2

CRN 1077-28-7
CMF C8 H14 O2 S2RN 816416-98-5 HCAPLUS
CN L-Tyrosine, mixt. with 2-(acetyloxy)-3-carboxy-N,N,N-trimethyl-1-propanaminium inner salt and 1,2-dithiolane-3-pentanoic acid (9CI) (CA INDEX NAME)

CM 1

CRN 14992-62-2
CMF C9 H17 N O4


CM 2

CRN 1077-28-7
CMF C8 H14 O2 S2

CM 3

CRN 60-18-4
CMF C9 H11 N O3

Absolute stereochemistry. Rotation (-).



L18 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 2004:905631 HCAPLUS

DN 141:384305

TI Basic salt of thioctic acid with L-carnitine

IN Salvi, Annibale; Villani, Flavio; Nardi, Antonio; De Angelis, Bruno

PA Italy

SO U.S. Pat. Appl. Publ., 5 pp.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004214879	A1	20041028	US 2003-698451	20031103
	WO 2004094403	A1	20041104	WO 2003-EP12179	20031031
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO,				

NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ,
TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,
TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI IT 2003-MI831 A 20030422

AB A process for the preparation of a salt of thioctic acid with L-carnitine is disclosed: Thioctic acid (50.5 g) are dissolved in 750 mL Me Et ketone at 20-25° and a solution of 15.5 g KOH pellets (0.249 mol) and 39.5 g (0.245 mol) L-carnitine in 200 mL MeOH are added dropwise in 15-20 min. The solution is heated to 30-35° and the solvent is distilled to reach an internal volume of 330-350 mL. After complete distillation 600 mL of Me Et ketone are added and the mixture is left 25-30° for 30 min. Thioctic carnitine potassium salt (77 g) is obtained.

IC ICM A61K031-385

ICS C07D339-02

INCL 514440000; 549039000

CC 63-6 (Pharmaceuticals)

Section cross-reference(s): 18

ST thioctic acid carnitine salt prepn; diet supplement thioctic acid carnitine salt prepn; pharmaceutical thioctic acid carnitine salt prepn

IT Alcohols, uses

RL: NUU (Other use, unclassified); PEP (Physical, engineering or chemical process); PYP (Physical process); PROC (Process); USES (Uses)

(C1-5; preparation of salt of thioctic acid with carnitine)

IT Drug delivery systems

(preparation of salt of thioctic acid with carnitine)

IT Esters, uses

RL: NUU (Other use, unclassified); PEP (Physical, engineering or chemical process); PYP (Physical process); PROC (Process); USES (Uses)

(preparation of salt of thioctic acid with carnitine)

IT Diet

(supplements; preparation of salt of thioctic acid with carnitine)

IT 248914-30-9P, (R)-(+) -Thioctic acid salt with L-carnitine

248914-32-1P, (S)-(-) -Thioctic acid salt with L-carnitine

248914-34-3P, Thioctic acid salt with L-carnitine

784200-62-0P 784200-63-1P 784200-65-3P

784200-67-5P

RL: FFD (Food or feed use); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of salt of thioctic acid with carnitine)

IT 75-05-8, Acetonitrile, uses

RL: NUU (Other use, unclassified); PEP (Physical, engineering or chemical process); PYP (Physical process); PROC (Process); USES (Uses)

(preparation of salt of thioctic acid with carnitine)

IT 541-15-1, L-Carnitine 1077-28-7, Thioctic acid

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of salt of thioctic acid with carnitine)

IT 248914-30-9P, (R)-(+) -Thioctic acid salt with L-carnitine

248914-32-1P, (S)-(-) -Thioctic acid salt with L-carnitine

248914-34-3P, Thioctic acid salt with L-carnitine

784200-62-0P 784200-63-1P 784200-65-3P

784200-67-5P

RL: FFD (Food or feed use); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of salt of thioctic acid with carnitine)

RN 248914-30-9 HCAPLUS


CN 1-Propanaminium, 3-carboxy-2-hydroxy-N,N,N-trimethyl-, (2R)-, (3R)-1,2-dithiolane-3-pentanoate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 248914-37-6

CMF C8 H13 O2 S2

Absolute stereochemistry. Rotation (+).




CM 2

CRN 44984-08-9

CMF C7 H16 N O3

Absolute stereochemistry. Rotation (-).



RN 248914-32-1 HCAPLUS


CN 1-Propanaminium, 3-carboxy-2-hydroxy-N,N,N-trimethyl-, (2R)-, (3S)-1,2-dithiolane-3-pentanoate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 248914-39-8

CMF C8 H13 O2 S2

Absolute stereochemistry. Rotation (-).




CM 2

CRN 44984-08-9

CMF C7 H16 N O3

Absolute stereochemistry. Rotation (-).




RN 248914-34-3 HCAPLUS

CN 1-Propanaminium, 3-carboxy-2-hydroxy-N,N,N-trimethyl-, (2R)-,
1,2-dithiolane-3-pentanoate (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 44984-08-9
CMF C7 H16 N O3

Absolute stereochemistry. Rotation (-).



CM 2

CRN 1077-29-8
CMF C8 H13 O2 S2



RN 784200-62-0 HCAPLUS

CN 1-Propanaminium, 3-carboxy-2-hydroxy-N,N,N-trimethyl-, (2R)-,
1,2-dithiolane-3-pentanoate, monopotassium salt (9CI) (CA INDEX NAME)


CM 1

CRN 248914-34-3
CMF C8 H13 O2 S2 . C7 H16 N O3

CM 2


CRN 44984-08-9
CMF C7 H16 N O3

Absolute stereochemistry. Rotation (-).



CM 3

CRN 1077-29-8
CMF C8 H13 O2 S2



RN 784200-63-1 HCAPLUS

CN 1-Propanaminium, 3-carboxy-2-hydroxy-N,N,N-trimethyl-, (2R)-, compd. with magnesium 1,2-dithiolane-3-pentanoate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 248914-34-3


CMF C8 H13 O2 S2 . C7 H16 N O3

CM 2

CRN 44984-08-9

CMF C7 H16 N O3


Absolute stereochemistry. Rotation (-).



CM 3

CRN 1077-29-8

CMF C8 H13 O2 S2




RN 784200-65-3 HCAPLUS

CN 1-Propanaminium, 3-carboxy-2-hydroxy-N,N,N-trimethyl-, inner salt, (2R)-, compd. with magnesium 1,2-dithiolane-3-pentanoate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 710351-22-7

CMF C8 H14 O2 S2 . 1/2 Mg




● 1/2 Mg

CM 2

CRN 541-15-1

CMF C7 H15 N O3

Absolute stereochemistry. Rotation (-).




RN 784200-67-5 HCAPLUS

CN 1-Propanaminium, 3-carboxy-2-hydroxy-N,N,N-trimethyl-, inner salt, (2R)-, compd. with calcium 1,2-dithiolane-3-pentanoate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 710351-21-6

CMF C8 H14 O2 S2 . 1/2 Ca




● 1/2 Ca

CM 2

CRN 541-15-1

CMF C7 H15 N O3

Absolute stereochemistry. Rotation (-).



L18 ANSWER 3 OF 4 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 1999:708603 HCAPLUS

DN 131:317793

TI Use of α -lipoic acid to reduce appetite and/or body weight

IN Dean, Joan; Schuhbauer, Hans; Von Seyerl, Joachim; Pischel, Ivo; Weiss, Stefan

PA SKW Trostberg A.-G., Germany

SO PCT Int. Appl., 24 pp.

CODEN: PIXXD2

DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9955331	A1	19991104	WO 1999-EP2776	19990423
	W: CA, CZ, HU, JP, NO, PL, US				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	DE 19818563	A1	19991028	DE 1998-19818563	19980425
	DE 19818563	C2	20030417		
PRAI	DE 1998-19818563	A	19980425		

OS MARPAT 131:317793

AB The invention relates to the use of R- α -lipoic acid and/or S- α -lipoic acid and/or one of its physiol. biocompatible salts to reduce appetite and/or body weight, at a preferred daily dose of between 10 mg and 10 g of the free acid form. Recommended single doses are between 10 mg and 5 g of either α -lipoic acid variant and are administered orally, especially to patients with a body mass index (BMI) >25 kg/m², preferably in the form of a nutritional supplement as part of an antiobesity therapy.

IC ICM A61K031-385

CC 1-10 (Pharmacology)

Section cross-reference(s): 18, 63

ST lipoic acid appetite body wt redn; obesity treatment nutritional supplement lipoic acid

IT Amino acids, biological studies

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(basic, α -lipoic acid salts; α -lipoic acid to reduce appetite and/or body weight)

IT Amines, biological studies

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(cyclic, α -lipoic acid salts; α -lipoic acid to reduce appetite and/or body weight)

IT Amines, biological studies

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(diamines, α -lipoic acid salts; α -lipoic acid to reduce appetite and/or body weight)

IT Nutrition, animal

(nutritional supplement; α -lipoic acid to reduce appetite and/or body weight)

IT Drug delivery systems

(oral; α -lipoic acid to reduce appetite and/or body weight)

IT Amines, biological studies

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(α -lipoic acid salts; α -lipoic acid to reduce appetite and/or body weight)

IT Antiobesity agents
Appetite depressants
Body weight

(α -lipoic acid to reduce appetite and/or body weight)

IT Alkali metal salts
Alkaline earth salts
Salts, biological studies

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(α -lipoic acid; α -lipoic acid to reduce appetite and/or body weight)

IT 1077-27-6, S- α -Lipoic acid 1077-27-6D, S- α -Lipoic acid, salts 1077-28-7, 1,2-Dithiolane-3-pentanoic acid 1077-28-7D, 1,2-Dithiolane-3-pentanoic acid, salts 1200-22-2, R- α -Lipoic acid 1200-22-2D, R- α -Lipoic acid, salts 14358-90-8 94599-85-6

137314-40-0 176110-58-0 176110-59-1 176110-60-4 176110-61-5

176110-66-0 176110-67-1 176110-68-2 176110-69-3 176110-75-1

176110-76-2 176110-79-5 176110-80-8 248913-97-5 248913-98-6

248913-99-7 248914-00-3 248914-01-4 248914-02-5 248914-03-6

248914-04-7 248914-05-8 248914-06-9 248914-07-0 248914-08-1

248914-09-2 248914-10-5 248914-11-6 248914-12-7 248914-13-8

248914-14-9 248914-15-0 248914-16-1 248914-17-2 248914-18-3

248914-19-4 248914-22-9 248914-25-2 248914-29-6 248914-30-9

248914-32-1 248914-34-3 248914-36-5 248914-38-7

248914-40-1 248914-41-2 248914-42-3 248914-43-4 248914-44-5

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(α -lipoic acid to reduce appetite and/or body weight)

IT 248914-30-9 248914-32-1 248914-34-3

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(α -lipoic acid to reduce appetite and/or body weight)

RN 248914-30-9 HCAPLUS


CN 1-Propanaminium, 3-carboxy-2-hydroxy-N,N,N-trimethyl-, (2R)-, (3R)-1,2-dithiolane-3-pentanoate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 248914-37-6

CMF C8 H13 O2 S2


Absolute stereochemistry. Rotation (+).



CM 2

CRN 44984-08-9
CMF C7 H16 N O3

Absolute stereochemistry. Rotation (-).




RN 248914-32-1 HCAPLUS
CN 1-Propanaminium, 3-carboxy-2-hydroxy-N,N,N-trimethyl-, (2R)-, (3S)-1,2-dithiolane-3-pentanoate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 248914-39-8
CMF C8 H13 O2 S2


Absolute stereochemistry. Rotation (-).



CM 2

CRN 44984-08-9
CMF C7 H16 N O3

Absolute stereochemistry. Rotation (-).




RN 248914-34-3 HCAPLUS
CN 1-Propanaminium, 3-carboxy-2-hydroxy-N,N,N-trimethyl-, (2R)-, 1,2-dithiolane-3-pentanoate (salt) (9CI) (CA INDEX NAME)


CM 1

CRN 44984-08-9
CMF C7 H16 N O3

Absolute stereochemistry. Rotation (-).



CM 2

CRN 1077-29-8
CMF C8 H13 O2 S2

RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 4 OF 4 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 1967:520167 HCAPLUS

DN 67:120167

TI Betaine or caritine thioctate for treatment of hepatic and anorectic complaints

PA Centre d'Etudes et de Realisations Therapeutiques (C.E.R.E.T.)

SO Fr. M., 3 pp.

CODEN: FMXXAJ

DT Patent


LA French

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	FR 4512		19661121	FR	19650518
AB	The salts are obtained by the reaction of thioctic acid with betaine or carnitine hydrate. The LD50 (white mice) of betaine thioctate (I) is 0.45 g./kg. by intraperitoneal and 5.6 g./kg. by oral application; the LD50 of carnitine thioctate (II) is 0.35 g./kg. by intraperitoneal and 3.8 g./kg. by oral application. The two products have hepato-protective and bioenergetic properties. They are effective against all hepatic insufficiencies when used as tablets, capsules, or drinking solns., e.g. 0.25 g. I or II in 10 ml. distilled water.				
IC	A61K; C07C; D				
CC	63 (Pharmaceuticals)				
ST	BETAINE THIOCTATE; CARNITINE THIOCTATE; LIVER INFECTION DRUG; APPETITE STIMULANT; BIOENERGETIC AGENT; HEPATO-PROTECTIVE AGENT; THIOCTIC ACID SALTS				
IT	Liver, diseases or disorders (betaine or carnitine thioctate in treatment of)				
IT	17747-20-5	18428-73-4	RL: BIOL (Biological study) (pharmaceutical compns. containing, in liver disorder treatment)		
IT	17747-20-5		RL: BIOL (Biological study) (pharmaceutical compns. containing, in liver disorder treatment)		
RN	17747-20-5 HCAPLUS				
CN	Ammonium, (3-carboxy-2-hydroxypropyl)trimethyl-, 1,2-dithiolane-3-valerate (8CI) (CA INDEX NAME)				

CM 1


CRN 44985-71-9
CMF C7 H16 N O3



CM 2

CRN 1077-29-8

CMF C8 H13 O2 S2



=>